ContraFect denied request to keep Nasdaq listing, shares down
27/01/2023 11:10
** Shares of drug developer ContraFect Corp CFRX.O down
22.2% at $0.07 in premarket trading
** CFRX said on Thursday it was denied request for continued
listing on Nasdaq Capital market
** On Nov. 22, co received letter from Nasdaq saying it did
not satisfy listing requirements
** Co added it continues to evaluate various alternative
courses of action to regain compliance with the Nasdaq Capital
Market listing requirements
** Stock fell ~96% last year
(Reporting by Tiyashi Datta in Bengaluru)
((tiyashi.datta@thomsonreuters.com))
Recent news on CONTRAFECT
See all newsBrief: Contrafect Corp - On Nov 7, Co Received Delisting Notification From Nasdaq Hearings Advisor Stating That Panel Determined To Delist Co's Common Stock
Brief: ContraFect Says Selling Securityholder May Offer And Selling Up To 7 Mln Shares In Aggregate Of Common Stock
Brief: Contrafect Announces FDA Clearance Of CF-370 IND Application To Proceed With Phase 1 Clinical Study
Brief: Contrafect Corp Says On Sept 21, Notified By Nasdaq, That Co Not In Compliance With The Minimum Bid Price Requirement
Brief: Contrafect Announces Submission Of Ind Application To The FDA For Its Development Candidate Cf-370